Up­dat­ed: Sam­sung Bio leans in­to ADC, gene ther­a­py is an ‘area of in­ter­est’

South Ko­rea-head­quar­tered Sam­sung Bio is heav­i­ly ex­pand­ing its an­ti­body-drug con­ju­gate ca­pa­bil­i­ties and that gene ther­a­py is an “area of in­ter­est,” head of glob­al sales Kevin Sharp told End­points News. But Sharp was quick to note that the man­u­fac­tur­er does not want to “over­sat­u­rate” its of­fer­ings and would “be care­ful” where it in­vests.

In a move to bol­ster its ADC of­fer­ings, a new stand-alone fa­cil­i­ty is set to go live in Oc­to­ber this year and be op­er­a­tional in April 2025. Con­struc­tion for the fa­cil­i­ty in Song­do, about a half an hour dri­ve from Seoul, start­ed in March last year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER